The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move that advances innovation in the digital health sector, Abbott has secured European regulatory approval (CE mark) for its Libre Duo and Libre Duo 10 Day systems. These represent the world's first continuous biowearables capable of monitoring both glucose and ketone levels simultaneously through a single sensor. The systems are designed to help diabetic patients detect early signs of diabetic ketoacidosis (DKA), a life-threatening complication, by providing dual-track metabolic data in real-time.
Sign in to access this content
Sign InThis approval comes amid intensifying competition in the continuous glucose monitoring (CGM) market, as Abbott seeks to maintain its edge over primary rival Dexcom (DXCM). According to market data, Abbott's diabetes care division has seen robust growth in recent quarters, fueled by the global success of the FreeStyle Libre franchise. This new certification grants the company a first-to-market advantage in Europe ahead of a potential US launch pending FDA clearance.
Operationally, ABT stock remained at key trading levels as of the close on May 27, 2026, with investors focusing on how these new biowearables will impact future profit margins. Looking ahead at the economic calendar, markets are awaiting Consumer Confidence data from Germany and the Eurozone on May 22, 2026, which may signal purchasing power trends in the regions where these devices will first be deployed.